TAKEDA PHARMACEUTICAL CO LTD
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Sep 30, 2025, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2025-09-30, active share 100.0%; sector active share 90.8% against the combined 13F book's sector weights.
Over time 8 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
8 tracked positions · as of Sep 30, 2025 · Δ vs Jun 30, 2025Portfolio Trend
Sector Breakdown
As of Sep 30, 2025| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $16,369,652 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | +13,722 | 54,887 | $891,364 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reducedNew Positions
Positions the filer opened this quarterSold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| — | 6,724,000 | $0 | ||
| — | 895,824 | $0 | ||
| — | 36,835 | $0 | ||
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
Held | 7,531,996 | $9,791,594 | 59.82% | |
| EQ |
Equillium, Inc.
Healthcare
|
Held | 1,824,977 | $2,609,717 | 15.94% | |
| XLO |
Xilio Therapeutics, Inc.
Healthcare
|
Held | 1,475,121 | $1,243,527 | 7.60% | |
| STTK |
Shattuck Labs, Inc.
Healthcare
|
Held | 515,619 | $1,232,329 | 7.53% | |
| LYEL |
Lyell Immunopharma, Inc.
Healthcare
|
Added | 54,887 | $891,364 | 5.45% | |
| AMWL |
American Well Corp
Healthcare
|
Held | 77,733 | $478,057 | 2.92% | |
| RANI |
Rani Therapeutics Holdings, Inc.
Healthcare
|
Held | 203,190 | $101,595 | 0.62% | |
| LAB |
Standard Biotools Inc.
Healthcare
|
Held | 16,515 | $21,469 | 0.13% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.